# IBI343 in Combination Therapy for Advanced Malignant Solid Tumors

> **NCT07483554** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 389 (estimated)

## Conditions studied

- CLDN18.2 Positive
- Gastric/Gastroesophageal Junction Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** IBI343,Gemcitabine, Albumin-bound Paclitaxel

## Key facts

- **NCT ID:** NCT07483554
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-25
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 389 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483554, "IBI343 in Combination Therapy for Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07483554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*